STOCK TITAN

BiomX Inc. - $PHGE STOCK NEWS

Welcome to our dedicated page for BiomX news (Ticker: $PHGE), a resource for investors and traders seeking the latest updates and insights on BiomX stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BiomX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BiomX's position in the market.

Rhea-AI Summary
BiomX Inc. (PHGE) to Host Virtual KOL Event to Discuss Positive Trial Results for BX004 in Cystic Fibrosis Patients with Chronic P. aeruginosa Infections
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
conferences clinical trial
-
Rhea-AI Summary
BiomX Inc. (NYSE American: PHGE) announced positive safety and efficacy results from Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis. The study showed clinically meaningful improvement in pulmonary function, significant reduction in P. aeruginosa burden, and plans to advance the BX004 program into a pivotal Phase 2b/3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-46.43%
Tags
-
Rhea-AI Summary
BiomX Inc. (NYSE American: PHGE) reported financial results and a business update for Q3 2023, including the ongoing analysis of Part 2 data from the Phase 1b/2a trial of BX004, with an expected announcement later this month. The company also highlighted the positive Part 1 data and FDA Fast Track designation for BX004, emphasizing its potential in treating chronic respiratory infections in cystic fibrosis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
Rhea-AI Summary
BiomX to present data from Phase 1b/2a study on BX004 for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients at the 37th Annual North American Cystic Fibrosis Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
conferences clinical trial
-
Rhea-AI Summary
BiomX appoints Edward L. Williams to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
management
-
Rhea-AI Summary
BiomX completes patient dosing in Phase 1b/2a trial for BX004, on track to report results in November 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
Rhea-AI Summary
BiomX CEO to present at H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
BiomX Inc. reports financial results and provides a business update for Q2 2023. Patient screening completed in Part 2 of Phase 1b/2a trial of BX004. FDA grants BX004 Fast Track designation. Initial data from Part 2 expected in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
Rhea-AI Summary
BiomX Inc. will host a conference call and live webcast on August 9th, 2023, to report second quarter 2023 financial results and provide business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences earnings
BiomX Inc.

NYSE:PHGE

PHGE Rankings

PHGE Stock Data

19.11M
32.39M
29.82%
25.72%
0.4%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
NESS ZIONA

About PHGE

biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.